Dendreon Clinical Studies Continue to Impress

It is one day after the House Energy and Commerce Committee sent a declination letter to the four Congressmen that had been requesting a further review of the questionable FDA ruling for Dendreon’s (DNDN) Provenge, the company’s groundbreaking Prostate cancer drug. Now, a news release shows another beneficial study result that should have the FDA looking even more ridiculous.

According to the HSE Committee, represented by Chairman John Dingell (D-MI) writes, “An investigative hearing prior to an agency’s final decision runs the risk of interfering with the normal regulatory process.” (click for letter) (pdf file)

The news looks promising. But realize, so did the last report, and the one before that as well.

SEATTLE and SAN FRANCISCO, Feb 14, 2008 /PRNewswire-FirstCall via COMTEX/ — Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented data demonstrating the correlation of a measure of the cumulative potency of PROVENGE (sipuleucel-T), an investigational active cellular immunotherapy for hormone-refractory prostate cancer, with overall survival. This the first time that an association between higher potency of an active immune therapy and increased patient survival has been reported. The correlation appeared to be independent of other important baseline prognostic factors.

The abstract (#21), “Cell Number and CD54 Expression in Sipuleucel-T correlate with Survival in Metastatic Androgen Independent Prostate Cancer,” is being presented at the American Society of Clinical Oncology’s 2008 Genitourinary Symposium in San Francisco.

In two Phase 3 trials, D9901 and D9902A, researchers evaluated cumulative product release parameters of PROVENGE, including CD54 upregulation (a measure of product potency defined as the increase of CD54 molecules expressed on antigen Presenting Cells [APC] after incubation with the PROVENGE Antigen Delivery Cassette[TM]) and the number of total nucleated cells [TNCs] among patients treated with sipuleucel-T (n=146). CD54 is a costimulatory molecule which serves as a marker for APCs. Its expression is increased when APCs become activated and this upregulation of CD54 serves as a potency release assay for PROVENGE.

Results showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients’ baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022).

“We have been able to show a correlation between patient survival and a measure of the cumulative potency of PROVENGE; such a correlation between product potency and clinical outcome has not been previously demonstrated with an active immunotherapy,” said Mark Frohlich, MD, chief medical officer of Dendreon. “These data provide further evidence that sipuleucel-T is actively engaging the immune system in a clinically meaningful way that prolongs patient survival.”

click to enlarge

Disclosure: Horowitz & Company Clients are long DNDN

Comments

[kyoto27:]

A 'thoughtful' observation from an observor of Congress and Biotechland:

“We find it ironic this word would come down on a day when Congress could find an entire half day to berate a baseball player for taking performance-enhancing drugs. If Roger Clemens is harmed from taking these drugs (assuming for a moment he did), he (a) made his own choices and now has to live with them, and (b) he has more than enough money to buy himself some pretty nice healthcare.

Contrast that with prostate cancer patients. They don’t get a choice. The FDA took it away from them. It isn’t just one man, it’s thousands—perhaps reaching tens of thousands by the time Provenge is finally on the market.



Apparently the Senate decides where it will focus based upon not whether the issues are worthy of Congressional attention, but the likelihood of whether they can get their mugs on cable news for a few hours.

They ought to be ashamed. And we mean really ashamed.”

2008 Feb 14 12:17 PM

[Ames Tiedeman:]

I am a skeptic. I am not sure they have an approvable drug here. The data looked weak to me. I am not sure they even conducted the last test in a way that the FDA would deem responsible and proper. The FDA said no already. What can change this? Does their process of treating the Prostate work, or can they just manipulate the data to make it appear it works to the layman?

2008 Mar 13 03:18 PM